Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497072 | 0.87 | GSK3B (1.00) | GSK3BCYP1A2 | |
| SCHEMBL1461358 | 0.86 | GSK3B (1.00) | GSK3BHDAC1HDAC2HDAC8 | |
| SCHEMBL6491225 | 0.83 | GSK3B (0.82) | GSK3BHDAC1HDAC2HDAC8CYP1A2 | |
| SCHEMBL15484479 | 0.83 | GSK3B (0.90) | GSK3BCYP1A2 | |
| SCHEMBL1461456 | 0.82 | GSK3B (0.77) | GSK3BHDAC1HDAC2HDAC8 | |
| SCHEMBL1461244 | 0.82 | GSK3B (0.76) | GSK3BHDAC1HDAC2HDAC8 | |
| SCHEMBL1460369 | 0.80 | GSK3B (0.74) | GSK3BHDAC1HDAC2HDAC8 | |
| SCHEMBL27604440 | 0.80 | GSK3B (0.74) | GSK3BHDAC1HDAC2HDAC8 | |
| SCHEMBL1460219 | 0.79 | GSK3B (0.71) | GSK3BHDAC1HDAC2HDAC8 | |
| SCHEMBL1461243 | 0.78 | GSK3B (0.84) | GSK3BHDAC1HDAC2HDAC8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | claimed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | GSK3B 2342/4885HDAC1 1547/4885HDAC2 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.